title: Verification of the newly proposed T category (seventh edition of the tumor, node, and metastasis classification) from a clinicopathological viewpoint in non-small cell lung cancer-special reference to tumor size.
abstract: BACKGROUND
  This study first verified the T classification, which is the major point of the revision regarding the seventh Tumor, Node, and Metastasis classification, from a viewpoint of the clinicopathological findings at the primary tumor site in non-small cell lung cancer.
  
  
  METHODS
  The medical records of 1393 patients with non-small cell lung cancer who underwent a complete resection at this hospital from 1974 to 2003 were thoroughly reviewed for pathologic findings and survival.
  
  
  RESULTS
  According to greatest dimension of the primary tumors, the 5-year postoperative survival was 77.8% for T1a (< or =2 cm), 63.3% for T1b (< or =3 cm), 46.4% for T2a (< or =5 cm), 38.8% for T2b (<7 cm), and 21.4% for T3 (>7 cm). The differences among those new T categories were all statistically significant. The incidence of lymphatic permeation within the primary tumor was 17.2% for T1b and 29.8% for T2a (T1b versus T2a, p < 0.05). The incidence of vascular invasion within the primary tumor was 24.9% for T1b, 35.3% for T2a, and 54.2% for T2b (T1b versus T2a and T2a versus T2b, p < 0.05). On the other hand, the incidence of pleural invasion of the primary tumor was 18.1% for T1a, 29.4% for T1b, 49.3% for T2a, 47.3% for T2b, and 87.5% for T3 (T1a versus T1b, T1b versus T2a, T2b versus T3, p < 0.05). Significant differences were observed among the newly revised T subsets in at least one incidence of lymphatic, vascular, or pleural invasion.
  
  
  CONCLUSIONS
  The new T classification, which is based mainly on the tumor size, is therefore considered to be appropriate for the pathologic findings of the primary tumor.
authors.affiliation: Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University Fukuoka, Japan. tokujiro@surg2.med.kyushu-u.ac.jp
authors.forename: Tokujiro
authors.initials: T
authors.lastname: Yano
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Morodomi
authors.forename: Kensaku
authors.initials: K
authors.lastname: Ito
authors.forename: Tsukihisa
authors.initials: T
authors.lastname: Yoshida
authors.forename: Akira
authors.initials: A
authors.lastname: Haro
authors.forename: Fumihiro
authors.initials: F
authors.lastname: Shoji
authors.forename: Takaomi
authors.initials: T
authors.lastname: Koga
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Maehara
mesh_terms: D000230:Adenocarcinoma / Q000145:classification / Q000473:pathology* / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000145:classification* / Q000473:pathology* / Q000601:surgery; D002294:Carcinoma, Squamous Cell / Q000145:classification / Q000473:pathology* / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000145:classification / Q000473:pathology* / Q000601:surgery; D008297:Male; D008499:Medical Records; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D015996:Survival Rate; D055815:Young Adult